All lobbying filings

BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

Lobbying for BOEHRINGER INGELHEIM USA CORPORATION · Lobbyists

Filing 2nd Quarter - Amendment

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $990,000.00 expenses · posted Mar 10, 2026

Official filing document

Bills named in this filing 5

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
S 832
EPIC Act of 2025
HR 8467
ZOMBIE Act
HR 3419
To amend the Public Health Service Act to reauthorize the telehealth network and telehealth resource centers grant prog…
S 1666
Improving Social Security’s Service to Victims of Identity Theft Act

Lobbying activity 4

Health Issues

Issues related to prescription drug pricing and value Prescription drug manufacturing and supply chains Issues related to 340B program Issues related to tax and tariffs Issues related to Intellectual Property Issues related to Inflation Reduction Act

Medicare/Medicaid

Education about chronic kidney disease and Medicare screening guidelines Issues related to Medicare Part D redesign Issues related to prescription drug pricing and value Issues regarding implementation of the Inflation Reduction Act, including H.R. 1492/S.832 - EPIC Act of 2025 Issues related to the Treat and Reduce Obesity Act The Access to Prescription Digital Therapeutic Act Issues related to Most Favored Nation Proposals

Animals

Issues related to Animal Health Issues related to One Health Issues Related to Compounding Animal Drugs from Bulk Substances Far, Food and National Security Act of 2024 (H.R. 8467) Foreign Animal Disease Prevention Surveillance and Rapid Response Act of 2023 (H.R. 3419/S.1666)

Budget/Appropriations

Issues related to FY2026 Appropriations

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.